Do Combination Therapies Hold Hope for Prostate Cancer Patients?
A phase 1 trial shows promise in treating metastatic prostate cancer with a single priming dose of radioligand therapy and immunotherapy.
University of California San Francisco
Give to UCSFA phase 1 trial shows promise in treating metastatic prostate cancer with a single priming dose of radioligand therapy and immunotherapy.
UCSF's Adam Boxer, MD, PhD, and Harvard neurologist Reisa Sperling, MD, review the history of clinical trials over the past 30 years in Alzheimer’s research with what was learned and how new biomarkers and clinical trial approaches are being used to find more effective treatments in a more efficient way than in the past.
A UCSF-led found that people who are experiencing homelessness have a 16-fold higher rate of sudden death from heart attacks, as well as other causes.
A study found that children who were recently diagnosed with type 1 diabetes need less supplemental insulin to keep their blood sugar in a healthy range if they use the immunotherapy drug teplizumab.
UCSF experts to discuss amyloid therapies and dementia research at CTAD conference, addressing equity, novel treatments, and innovative studies.
Scientists found that the nervous system tamps down allergic response, which could change how asthma, Crohn’s and other inflammatory diseases are treated.
A new study will combine an Alzheimer’s medication that slows disease progression in some patients with two other drugs to see if their effects can be amplified.
FDA approves palovarotene (Sohonos) for rare FOP, reducing HO by 54%. Significant step in improving lives of affected patients.
Convergent evolutionary mechanisms shared by COVID-19 variants allow them to overcome both adaptive and innate immune system barriers.
A clinical trial showed that MDMA, the so-called psychedelic drug also known as "ecstasy" or "molly," can be a powerful new tool in treating people with moderate-to-severe PTSD.
The FDA recently approved the world’s first vaccines to prevent RSV for infants and elderly adults.
A new report from the Lancet Commission on tuberculosis releases recommendations, providing a path forward to turn the tide on this preventable, treatable and curable disease.
UCSF researchers are working across disease specialties. Diabetes researchers are looking at how oncologists use CAR T-cell therapy to reprogram a person’s immune system to attack cancer cells, for example. They hope to similarly reprogram the immune system to fight diabetes.
A brain implant and digital avatar allow a paralyzed stroke survivor to speak with for first time in 18 years with the help of artificial intelligence.
Gal-3C, a galectin-3 inhibitor, shows promise in limiting post-MI scarring, improving cardiac function, and outperforming current therapies.
Study finds DOACs may lower recurrent VTE risk over warfarin in extended treatment. Observational evidence supports DOAC use.
A newly identified platelet factor 4 (PF4) was found to help rejuvenate the old brain and boost the young brain, potentially opening the door to new therapies that aim to restore brain function
A new digital headset designed to measure alterations in brain function could change decisions about how quickly an athlete is ready to return to play after a concussion.
Long COVID symptoms can persist for a year after initial infection, or re-emerge months later after disappearing.
An experimental blood test that reflects injury to nerve cells from multiple sclerosis (MS) was found to work for children with MS and other neurological conditions, even when they are symptom-free.